Built on a foundation of interactive video and audio patient data
Accurate confirmation of medication ingestion
Validated against plasma blood levels
20% - 60% improvements according to blood levels
Rich data fuels predictive insights
Over 1 Million behavioral interactions with IMA
In drug development, we are defining new methodologies and enrichment strategies
Clear value is essential in understanding the application of new technology. AiCure’s value is structured around four key pillars: data integrity; lower variability; predictive composite measures; and increases in statistical power. Incorporating these data pillars into study design allows for faster, smaller trials. AiCure is also demonstrating significant results by introducing new trial methodologies such as placebo lead-in periods, micro-reimbursements, and other approaches directly correlated with patient engagement and clinical endpoints.
For payors, we are reducing medical costs and waste
Medication adherence is one of the few parameters in healthcare that is directly linked to medical costs. AiCure has demonstrated significant savings for some of the largest payors and states by ensuring high-risk patient populations stay on therapy.
For science and the healthcare industry, we are developing novel clinical endpoints through computational diagnostics
AiCure is pioneering a new set of tools to help researchers and clinicians understand and predict how patients respond to treatment. Advances in artificial intelligence allow computers to capture physiological datapoints that characterize expressivity, psychomotor function, and cognition. Whether a patient has schizophrenia or congestive heart failure, the degree to which they are able to adhere and respond to treatment depends in great part on their mood, their ability to move and to concentrate. AiCure is leading a multi-stakeholder R&D effort with industry and academia to develop these transdiagnostic domains and novel sensitive endpoints.
Artificial Intelligence in Life Sciences: The Formula for Pharma Success across the Drug Lifecycle
Artificial Intelligence in Life Sciences: The Formula for Pharma Success across the Drug Lifecycle By Clay Heskett, Ben Faircloth…
NeuroBo Selects AiCure to Advance Pivotal Neuropathic Pain Clinical Trial
AiCure, a behavioral data analytics company targeting the healthcare and life sciences industries, today announced …
Digital Tech Exploded in 2018: Will 2019 See Broad Adoption?
Awareness around the potential opportunities created by artiﬁcial intelligence has never been higher, but pharma’s biggest challenge in 2019 will…
Building a High-Tech, High-Touch Model for Drug Management
Caroline Carney, MD, MSc Caroline Carney, MD, MSc, is the chief medical officer for Magellan Rx Management, the pharmacy…
AiCure's Revenue Soars as it Bolsters Client List and Executive Team
NEW YORK, Dec. 3, 2018 /PRNewswire/ — AiCure, a behavioral data analytics company targeting the healthcare…
Intellectual property - Over 100 patents filed